{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.22","upperLimit":"83.92","value":"72.6"},{"groupId":"OG001","lowerLimit":"54.35","upperLimit":"78.86","value":"66.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"description":"The Investigator assessed the overall severity of Psoriasis (PSO) using the following 5-point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.","dispersionType":"95% Confidence Interval","groups":[{"description":"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg Q2W from Week 6 to Week 14.\n\nTreatment received from Week 16 - 48 was based on initial treatment and response to treatment:\n\n* PASI50 responders at Week 16 continued to receive CZP 200 mg Q2W.\n* PASI50 non-responders at Week 16 were removed from blinded study medication and escaped to unblinded CZP 400 mg Q2W. Participants who received unblinded CZP 400 mg Q2W for 16 weeks and did not achieve a PASI50 response were withdrawn from the study.\n* PASI50 non-responders at Week 32 or a later time point were withdrawn from the study.\n\nParticipants who completed the Maintenance Period (with PASI50 response at Week 48) entered the OLE Period on CZP 200 mg Q2W.\n\nWeek 48 completers in the escape arm continued to receive CZP 400 mg Q2W or may have switched to CZP 200 mg Q2W.\n\nDepending on PASI50 or PASI75 responses at Week 60 or a later time point, participants may have switched to CZP 400 mg Q2W or withdrew from the study.\n\nParticipants formed the RS.","id":"OG000","title":"CZP 200 mg Q2W (RS)"},{"description":"CZP 400 mg Q2W through Week 14.\n\nTreatment received from Week 16 - 48 was based on initial treatment and response to treatment:\n\n* PASI50 responders at Week 16 continued to receive CZP 400 mg Q2W.\n* PASI50 non-responders at Week 16 were removed from blinded study medication and escaped to unblinded CZP 400 mg Q2W. Participants who received unblinded CZP 400 mg Q2W for 16 weeks and did not achieve a PASI50 response were withdrawn from the study.\n* PASI50 non-responders at Week 32 or a later time point were withdrawn from the study.\n\nParticipants who completed the Maintenance Period (with PASI50 response at Week 48) entered the OLE Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continued to receive CZP 400 mg Q2W or may have switched to CZP 200 mg Q2W.\n\nParticipants who achieved a PASI75 response during the OLE Period may have switched to CZP 200 mg Q2W.\n\nParticipants formed the RS.","id":"OG001","title":"CZP 400 mg Q2W (RS)"}],"paramType":"NUMBER","populationDescription":"The Randomized Set (RS) included all participants randomized into the study. Missing data were handled using the Markov Chain Monte Carlo (MCMC) method for multiple imputation.","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Proportion of Participants Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 48","type":"SECONDARY","unitOfMeasure":"percentage of participants"}